Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07379827 · ClinicalTrials.gov registry record
Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)
A clinical trial of Schizophrenia, sponsored by Bristol-Myers Squibb.
- Recruiting
- Registry status
- 1,500
- Enrollment target
- 20
- Study locations
NCT07379827: Recruiting study of Schizophrenia, sponsored by Bristol-Myers Squibb.
NCT07379827 is a study of Schizophrenia that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 1,500 participants, above the 214-participant average among 315 other Schizophrenia trials with a reported enrollment target (601% higher). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07379827, a study of Schizophrenia, is actively recruiting participants, sponsored by Bristol-Myers Squibb.
- RECRUITING
- Registry status
- 1,500 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to describe real-world treatment patterns, effectiveness and adverse events of adults diagnosed with schizophrenia that have initiated xanomeline and trospium chloride (KarXT) treatment in the United States
Conditions Studied
Interventions
- DRUG Xanomeline and trospium chloride (KarXT)
Study Locations (20)
Florida
- Local Institution - 0005 - Bonita Springs
- Local Institution - 0019 - Hialeah
- Local Institution - 0030 - Homestead
- Local Institution - 0029 - Kendall
- Local Institution - 0032 - Miami
- Local Institution - 0011 - Miami
- Local Institution - 0007 - Miami
- Local Institution - 0006 - Miami
- Local Institution - 0023 - Orange City
California
- Local Institution - 0003 - Anaheim
- Local Institution - 0012 - La Palma
- Local Institution - 0028 - Stanford
New York
- Local Institution - 0004 - Monsey
- Local Institution - 0020 - White Plains
Arkansas
- Local Institution - 0009 - Bryant
Georgia
- Local Institution - 0025 - Atlanta
Michigan
- Local Institution - 0014 - Bloomfield Township
North Carolina
- PPD Virtual - PPD - US - Wilmington
Ohio
- Local Institution - 0031 - Mason
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,500 participants |
| Start Date | 2026-02-26 |
| Est. Completion | 2028-06-20 |
What NCT07379827 shows while recruiting
NCT07379827 is an observational study that tracks outcomes without assigning an intervention. Its 1,500 participants enrollment target places it among the larger protocols in the corpus, above the 214-participant average among 315 other Schizophrenia trials with a reported enrollment target (601% higher).
The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 1 intervention - of which Xanomeline and trospium chloride (KarXT) is the first listed.
NCT07379827 names 20 study sites across 9 states, led by Florida, California, New York.
Frequently Asked Questions
What is clinical trial NCT07379827 about?
NCT07379827 is a clinical study titled "Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)". The purpose of this study is to describe real-world treatment patterns, effectiveness and adverse events of adults diagnosed with schizophrenia that have initiated xanomeline and trospium chloride (KarXT) treatment in the United States
What is the current status of trial NCT07379827?
This trial is currently recruiting. The enrollment target is 1,500 participants. The study started on 2026-02-26. Estimated completion is 2028-06-20.
What conditions does trial NCT07379827 study?
This clinical trial studies the following conditions: Schizophrenia.
What interventions are being tested in trial NCT07379827?
The interventions under investigation include: Xanomeline and trospium chloride (KarXT) (DRUG).
Who is sponsoring clinical trial NCT07379827?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07379827 being conducted?
This trial has 20 study locations across Arkansas, California, Florida, Georgia, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07379827's enrollment target sits among peer trials
1,500 4th of 315 higher than 312 of 315 other Schizophrenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Taking Action for College Students
RECRUITING · NA
-
Tolerability of MDMA in Schizophrenia
RECRUITING · Phase 1
-
Enhancing Prefrontal Oscillations and Working Memory in Early-course Schizophrenia
RECRUITING · NA
-
Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia
RECRUITING · Phase 4
-
Getting Out of the House: Using Behavioral Activation to Increase Community Participation
RECRUITING · NA
-
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00178724 · 1,500 participants
Spinal Cord Injury Registry - North American Clinical Trials Network
- NCT00951366 · 1,500 participants
Preterm Lung Patient Registry
- NCT01050504 · 1,500 participants
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
- NCT02071134 · 1,500 participants
Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI